Artificial Intelligence Drug R&D Market Report – Research, Industry Analysis Reports and Market Demands

Global Artificial Intelligence Drug R&D Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report

Buy now

Table of Content

1 Market Overview

2 Company Profiles

3 Market Competition, by Players

3.1 Global Artificial Intelligence Drug R&D Revenue and Share by Players (2021-2026)
3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Artificial Intelligence Drug R&D by Company Revenue
- 3.2.2 Top 3 Artificial Intelligence Drug R&D Players Market Share in 2025
- 3.2.3 Top 6 Artificial Intelligence Drug R&D Players Market Share in 2025
3.3 Artificial Intelligence Drug R&D Market: Overall Company Footprint Analysis
- 3.3.1 Artificial Intelligence Drug R&D Market: Region Footprint
- 3.3.2 Artificial Intelligence Drug R&D Market: Company Product Type Footprint
- 3.3.3 Artificial Intelligence Drug R&D Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

4.1 Global Artificial Intelligence Drug R&D Consumption Value and Market Share by Type (2021-2026)
4.2 Global Artificial Intelligence Drug R&D Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

5.1 Global Artificial Intelligence Drug R&D Consumption Value Market Share by Application (2021-2026)
5.2 Global Artificial Intelligence Drug R&D Market Forecast by Application (2027-2032)

6 North America

6.1 North America Artificial Intelligence Drug R&D Consumption Value by Type (2021-2032)
6.2 North America Artificial Intelligence Drug R&D Market Size by Application (2021-2032)
6.3 North America Artificial Intelligence Drug R&D Market Size by Country
- 6.3.1 North America Artificial Intelligence Drug R&D Consumption Value by Country (2021-2032)
- 6.3.2 United States Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 6.3.3 Canada Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)

7 Europe

7.1 Europe Artificial Intelligence Drug R&D Consumption Value by Type (2021-2032)
7.2 Europe Artificial Intelligence Drug R&D Consumption Value by Application (2021-2032)
7.3 Europe Artificial Intelligence Drug R&D Market Size by Country
- 7.3.1 Europe Artificial Intelligence Drug R&D Consumption Value by Country (2021-2032)
- 7.3.2 Germany Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 7.3.3 France Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 7.3.5 Russia Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 7.3.6 Italy Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)

8 Asia-Pacific

8.1 Asia-Pacific Artificial Intelligence Drug R&D Consumption Value by Type (2021-2032)
8.2 Asia-Pacific Artificial Intelligence Drug R&D Consumption Value by Application (2021-2032)
8.3 Asia-Pacific Artificial Intelligence Drug R&D Market Size by Region
- 8.3.1 Asia-Pacific Artificial Intelligence Drug R&D Consumption Value by Region (2021-2032)
- 8.3.2 China Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 8.3.3 Japan Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 8.3.5 India Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 8.3.7 Australia Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)

9 South America

9.1 South America Artificial Intelligence Drug R&D Consumption Value by Type (2021-2032)
9.2 South America Artificial Intelligence Drug R&D Consumption Value by Application (2021-2032)
9.3 South America Artificial Intelligence Drug R&D Market Size by Country
- 9.3.1 South America Artificial Intelligence Drug R&D Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)

10 Middle East & Africa

10.1 Middle East & Africa Artificial Intelligence Drug R&D Consumption Value by Type (2021-2032)
10.2 Middle East & Africa Artificial Intelligence Drug R&D Consumption Value by Application (2021-2032)
10.3 Middle East & Africa Artificial Intelligence Drug R&D Market Size by Country
- 10.3.1 Middle East & Africa Artificial Intelligence Drug R&D Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)
- 10.3.4 UAE Artificial Intelligence Drug R&D Market Size and Forecast (2021-2032)

11 Market Dynamics

11.1 Artificial Intelligence Drug R&D Market Drivers
11.2 Artificial Intelligence Drug R&D Market Restraints
11.3 Artificial Intelligence Drug R&D Trends Analysis
11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

12.1 Artificial Intelligence Drug R&D Industry Chain
12.2 Artificial Intelligence Drug R&D Upstream Analysis
12.3 Artificial Intelligence Drug R&D Midstream Analysis
12.4 Artificial Intelligence Drug R&D Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

14.1 Methodology
14.2 Research Process and Data Source

Description

According to our (Global Info Research) latest study, the global Artificial Intelligence Drug R&D market size was valued at US$ 751 million in 2025 and is forecast to a readjusted size of US$ 1325 million by 2032 with a CAGR of 7.9% during review period.
Artificial Intelligence Drug R&D (AI Drug Development) refers to a class of R&D methods and software/platform systems that utilize technologies such as machine learning, deep learning, generative models, and knowledge graphs to model and infer multi-omics and biomedical data throughout the entire drug development process, from target discovery to lead compounds, preclinical trials, clinical trials, and post-marketing. This aims to improve the accuracy of target selection, shorten the candidate drug discovery cycle, reduce the failure rate, and optimize trial design and patient stratification.
AI-driven drug development is transitioning from "proof of concept" to "deliverable productivity." On one hand, large pharmaceutical companies and platform companies are emphasizing interpretability, auditability, and compliance (GxP/data governance), embedding AI models into existing experimental automation, LIMS/ELN, cheminformatics, and clinical operations systems to form an "AI + experimental closed loop" (design–make–test–analyze). On the other hand, industry focus is shifting from single-point tools to end-to-end capabilities: for example, integrating target selection, molecular generation, ADMET, and clinical strategies, while enhancing model generalization capabilities through multimodal data (omics, imaging, EHR, literature, and patents), making AI more closely aligned with real-world R&D decisions.
Simultaneously, generative AI is reshaping the workflow of early-stage research and translational medicine: at the molecular and protein level, the combination of generation and screening (virtual screening + de novo design) is becoming more common; at the clinical level, real-world data and patient stratification are driving "more precise enrollment and endpoint selection" to reduce trial size or increase success rates. In terms of commercialization, the cooperation model has expanded from "software subscription" to "milestone/revenue sharing, joint R&D, and joint pipeline incubation", and places greater emphasis on quantifiable deliverables (hit rate, shortened cycle, candidate quality) and reproducible verification system.
This report is a detailed and comprehensive analysis for global Artificial Intelligence Drug R&D market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Artificial Intelligence Drug R&D market size and forecasts, in consumption value ($ Million), 2021-2032
Global Artificial Intelligence Drug R&D market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Artificial Intelligence Drug R&D market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Artificial Intelligence Drug R&D market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Artificial Intelligence Drug R&D
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Artificial Intelligence Drug R&D market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Insilico Medicine, Recursion, BenevolentAI, Atomwise, Recursion Pharmaceuticals, DeepMind（Google）, Insitro, Owkin, XtalPi, Verge Genomics, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Artificial Intelligence Drug R&D market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Software
Service
Market segment by Stage
Target Identification & Validation
Hit/Lead Discovery
Clinical Development & Trial Design
Others
Market segment by Technology
Machine Learning & Deep Learning
Generative Models
Knowledge Graph & NLP
Multi-omics / Multimodal Modeling
Market segment by Application
Pharmaceutical Companies
Biotechnology Companies
Contract Research Organizations（CRO)
Academic & Research Institutions
Others
Market segment by players, this report covers
Insilico Medicine
Recursion
BenevolentAI
Atomwise
Recursion Pharmaceuticals
DeepMind（Google）
Insitro
Owkin
XtalPi
Verge Genomics
Iktos
Valo Health
Standigm
Relay Therapeutics
Cyclica
Isomorphic Labs
Schrödinger
Absci
Genesis Therapeutics
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Artificial Intelligence Drug R&D product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Artificial Intelligence Drug R&D, with revenue, gross margin, and global market share of Artificial Intelligence Drug R&D from 2021 to 2026.
Chapter 3, the Artificial Intelligence Drug R&D competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Artificial Intelligence Drug R&D market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Artificial Intelligence Drug R&D.
Chapter 13, to describe Artificial Intelligence Drug R&D research findings and conclusion.

Buy now